Knoa Patent-Cliff Exposure & CMS Drug Spending Portfolio

Knoa (US): 5 reconciled FDA prescription therapies (86.6% 2025 to 2030 cliff risk), $458.9M 2024 CMS Part D & Medicaid spend, and 56 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies5
2025 to 2030 Patent-Cliff Revenue Exposure86.6%
Primary Portfolio LOE Date2030-01-01
2024 CMS Total Public Spend$458.9M
2024 Medicare Part D Spend$367.8M
2024 Medicaid Spend$91.2M
California HCAI SB 17 Filings56 WAC filings (max 441.7% 2-yr change)